2019 ESMO: What We Learned About MBC - Metastatic Breast Cancer Trial Talk

Conference Talk

The European Society for Medical Oncology held its annual meeting in Barcelona, Spain, Sept. 27-Oct.1.

Below you can find news specific to metastatic breast cancer patients that came out of this year’s conference. This includes new data from two studies that showed that treatment with a CDK4/6 inhibitor plus fulvestrant (Faslodex®) improved overall survival in women with hormone receptor-positive (HR+), HER 2-negative advanced breast cancer.

Last Modified on February 10, 2021



for past articles or specific information.